Ziopharm to Participate in Upcoming January Conferences marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the .
ZIOPHARM Oncology IncDecember 21, 2020 GMT
– Advances Eden BioCell’s clinical program to validate Rapid Personalized Manufacturing (RPM) –
– Clinical trial to study autologous CD19-specific CAR-T using RPM technology designed to reduce cost and simplify production for infusion the day after gene transfer –
BOSTON, Dec. 21, 2020 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that the Taiwan Food and Drug Administration has cleared an investigational new drug application (IND) from Eden BioCell, a joint venture between Ziopharm and cell therapy company TriArm Therapeutics, for its phase 1 clinical trial to evaluate patient-derived CD19-specific CAR-T, using Ziopharm’s Rapid Personalized Manufacturing (RPM) technology. Thi
Press Release : ARTIDIS investigates nanomechanical tissue signature to improve response to radio/immuno-therapy in lung cancer marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Ziopharm Comments on Consent Solicitation Results
Ziopharm Comments on Consent Solicitation Results
BOSTON, Dec. 16, 2020 Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, “WaterMill”). Based on the consents received by the Company, Jaime Vieser and Holger Weis have been formally elected to the Ziopharm Board of Directors (the “Board”), while Chairman Scott Tarriff will depart the Board effective immediately.
The Company’s statement is as follows:
“We sincerely thank our shareholders for all of the helpful feedback and constructive dialogue that they have shared with the Company since our 2020 Annual Meeting. We welcome Messrs. Vieser and Weis as the newest members of Ziopharm’s Board of Directors.